End-of-day quote
Other stock markets
|
||
- | - |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
01/05 | HSS Hire annual profit falls amid investment spending; CFO to depart | AN |
Sales 2024 * | 347M 440M 0 36.77B | Sales 2025 * | 360M 456M 0 38.09B | Capitalization | 67.26M 85.24M 0 7.12B |
---|---|---|---|---|---|
Net income 2024 * | 6M 7.6M - 635M | Net income 2025 * | 7M 8.87M - 741M | EV / Sales 2024 * | 0.47 x |
Net Debt 2024 * | 95.22M 121M 0 10.08B | Net Debt 2025 * | 99.75M 126M 0 10.56B | EV / Sales 2025 * | 0.46 x |
P/E ratio 2024 * |
10.8
x | P/E ratio 2025 * |
9.55
x | Employees | - |
Yield 2024 * |
6.05% | Yield 2025 * |
6.23% | Free-Float | 24.68% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Ashmore
CEO | Chief Executive Officer | 60 | 01/17/01 |
Paul Quested
DFI | Director of Finance/CFO | 54 | 01/16/01 |
Daniel Joll
BRD | Director/Board Member | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 09/15/09 | |
Director/Board Member | 71 | 09/15/09 | |
Alan Peterson
CHM | Chairman | 77 | 01/12/01 |
1st Jan change | Capi. | |
---|---|---|
+24.23% | 47.44B | |
+11.50% | 33.65B | |
+24.91% | 17.99B | |
-10.11% | 7.61B | |
+19.62% | 5.59B | |
+6.96% | 4.52B | |
-3.22% | 3.68B | |
-8.99% | 2.67B | |
+18.69% | 2.18B |